Skip to main content
. Author manuscript; available in PMC: 2017 Jul 1.
Published in final edited form as: Mol Cancer Ther. 2016 May 20;15(7):1691–1701. doi: 10.1158/1535-7163.MCT-16-0032

Figure 1. Comparison of CDK11 expression in primary, metastatic, and recurrent ovarian cancer.

Figure 1

A: Distribution of CDK11 immunohistochemical staining scores in primary, metastatic, and recurrent ovarian cancer. Statistical analysis was performed using a Student’s t-test (between two groups) to compare the CDK11 staining intensity scores among primary tumors, recurrent tumors, and tumors with metastasis, and P < 0.01 was accepted as a significant difference between means. B: Representative images of HE and CDK11 immunohistochemical staining in matched primary, metastatic, and recurrent ovarian cancers.